Abstract:The Janus kinase 2 (JAK2) gene is located on chromosome 9p24.1 and encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signaling. The JAK2 protein is especially important for controlling the production of blood cells from hematopoietic stem cells. In fact, the JAK2 mutation at amino acid 617 (Valine 617 to Phenylalanine, V617F) is the most frequently detected mutation in myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). This dominant gain-of-function V617F mutation results in constitutive tyrosine phosphorylation activity, leading to uncontrolled blood cell production, including increased numbers of erythrocytes, neutrophils, and platelets. To detect the JAK2 V617F mutation in DNA from patient blood samples, we developed a unique real-time PCR assay using our proprietary XNA technology that enables the assay to selectively amplify the mutant sequence by using a synthetic DNA analog XNA (Xenonucleic Acid). The JAK2 V617F mutation detection assay is designed to detect a valine-to-phenylalanine mutation at amino acid 617 (V617F). PCR primers, TaqMan probes, and XNA were designed for the JAK2 V617F mutation, along with primers and probes for an internal control gene in the duplex setting. The analytical performance of the assay was verified and validated using a variety of control samples. The results revealed that the XNA completely suppressed the amplification of wildtype sequence while only the V617F mutant sequence was amplified. The JAK2 V617F mutation detection assay is highly reproducible with intra- and inter-assay coefficients of variation of less than 10%. Results for the assay's analytical sensitivity indicated that V617F could be detected with about 0.25% mutant allele frequency in 10 ng DNA input. In addition, no significant cross-amplification between V617F and V617I was observed. Thus, the JAK2 V617F mutation detection assay is specific for the V617F mutation. The JAK2 V617F mutation detection assay, using XNA-based technology, provides high sensitivity and specificity to detect the JAK2 V617F mutation. Thus, this assay would be a useful tool for clinical decision-making in determining the presence of the JAK2 V617F mutation in DNA from patient blood samples. Citation Format: Shuo Shen, Robert Brown, Daniel Kim, Larry Pastor, Andrew Y. Fu, Pushpinder Kaur, Alisha Babu, Wei Liu, Aiguo Zhang, Hiromi Tanaka, Michael Y. Sha. A novel XNA technology-based assay to detect JAK2 V617F mutation by real-time PCR [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7295.

Development and Validation of a Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-Assay for Clinical JAK2 V617F Mutation Detection

Establishment and analytical validation of JAK2 V617F mutation assay by fluorescence PCR combined with melting curve analysis

Development And Inter-Laboratory Validation Of Unlabeled Probe Melting Curve Analysis For Detection Of Jak2 V617f Mutation In Polycythemia Vera

Detection of JAK2 V617F Mutation by Real-Time PCR

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Detection of the Jak2 Mutation in Myeloproliferative Neoplasms by Asymmetric Pcr with Unlabeled Probe and High-Resolution Melt Analysis

Performance evaluation of the automated SNPs analyzer for the detection of JAK2 V617F mutation

Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation

[Detection of JAK2V617F Mutation in Patients with Myeloproliferative Disorders with TaqMan-MGB Probe].

Establishment of a Rapid and Easy Method for Simultaneous Detection of FLT3-ITD and NPM1 Gene Mutations in Acute Myeloid Leukemia

Multiplex sequence-specific PCR detection for simultaneous screening of 5 types of JAK2 mutations in myeloproliferative diseases

Detecting JAK2 V617F Mutation in Myeloproliferative Neoplasms by Microarray Based Digital PCR

Abstract 7295: A novel XNA technology-based assay to detect JAK2 V617F mutation by real-time PCR

A Multiplex Snapback Primer System for the Enrichment and Detection Ofjak2v617f Andmplw515l/k Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Simultaneous Detection of JAK2 V617F Mutation and JAK2 Exon12 Mutations by Multiplex PCR and High-Resolution Melting Curve Analysis

A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.

Toward point-of-care testing for JAK2 V617F mutation on a microchip

MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR

A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms